• Drug-Sensitized Yeast for mTOR Inhibitor Discovery

  2026-08-31

  A 2025 GeroScience study introduces a drug-sensitized Saccharomyces cerevisiae platform that detects TOR pathway inhibitors at substantially lower concentrations than conventional yeast backgrounds. The system identifies known and candidate TOR inhibitors while showing no TOR-dependent growth signal for canagliflozin, illustrating how pathway-focused screening can separate mTOR activity from unrelated pharmacology.

• Palmitic acid: Practical Protocol and QC Guide

  2026-08-31

  Palmitic acid (SKU N2456) provides a characterized solvent-based fatty acid input for controlled studies of lipid metabolism, insulin signaling, inflammation, and protein palmitoylation. It should not be added directly to aqueous systems or retained as a long-term solution; fresh preparation, matched vehicle controls, and documented reconstitution are required.

• Silymarin as a Translational Research Probe

  2026-08-30

  Silymarin is more than a milk thistle extract: it is a chemically complex research probe for connecting redox biology, inflammation, cancer signaling, metabolic dysfunction, and antiviral mechanisms. This thought-leadership guide shows how to design mixture-aware, solubility-conscious workflows that convert broad biological activity into translationally useful evidence.

• Gepotidacin: Turning Topoisomerase Insight Into Translation

  2026-08-29

  Gepotidacin, also known as GSK2140944, offers translational researchers a mechanism-led framework for studying bacterial DNA replication inhibition, resistance, and pharmacology. This thought-leadership perspective moves beyond a conventional product description by connecting target engagement, orthogonal assay design, pathway-level thinking, and human pharmacokinetic modeling.

• Optimizing Calcium-Phosphate Transfection

  2026-08-28

  This 2026 study identifies the DNA concentration-to-reaction-volume balance as the central determinant of calcium-phosphate transfection efficiency in HEK 293T cells. Its optimized condition, 80 μg plasmid DNA in a 1 mL reaction for 2–3 × 10⁵ cells/mL, provides a practical, low-cost benchmark for improving plasmid delivery without relying exclusively on commercial reagents.

• Coumestrol: ER Antagonism and RA Ferroptosis

  2026-08-28

  Coumestrol is a phytoestrogen estrogen receptor antagonist with activity across ERα, ERβ, PXR, and CAR-related assays. In an in vitro rheumatoid arthritis model, Coumestrol reduced fibroblast-like synoviocyte proliferation and inflammation while inducing a PMAIP1-dependent ferroptosis response.

• Triacetin Digestion and Hepatic Metabolic Signaling

  2026-08-27

  A 2025 study in rats shows that triacetin is fully digested in the upper gastrointestinal tract and absorbed mainly as acetate and glycerol rather than reaching the colon intact. The work links glycerol delivery to hepatic gluconeogenesis and acetate exposure to AMPK activation, altered lipid-related gene expression, and a broader signaling role for a short-chain triacylglycerol.

• Ridaforolimus: mTOR Strategy for Translational Oncology

  2026-08-27

  Ridaforolimus, also known as Deforolimus or MK-8669, offers translational researchers a mechanistically defined way to interrogate mTOR signaling, tumor-cell proliferation, VEGF production, and combination-response biology. This thought-leadership article connects its oncology applications with machine-learning-enabled senolytic discovery while clearly separating established evidence from forward-looking hypotheses.

• ABT-199 Workflows for Mitochondrial Apoptosis

  2026-08-26

  ABT-199 (Venetoclax) provides a selective way to test BCL-2 dependence in hematologic malignancy models without treating every viability change as nonspecific toxicity. This workflow pairs dose-response apoptosis assays with the 2025 RNA Pol II findings to separate mitochondrial death signaling from transcriptional collapse.

• Prednisone: From Mechanism to Translational Impact

  2026-08-26

  Prednisone is more than a broad immunosuppressive control: its effects on lymphocyte cell-cycle progression, IL-2 signaling, and apoptosis create a tractable framework for translational research. This article connects assay design, chemical handling, neurobiological risk assessment, and digestion-aware analytical thinking to help researchers extract more defensible conclusions from Prednisone studies.

• PEX5, Taurine, and Lung Fibroblast Senescence

  2026-08-25

  This study identifies a peroxisome-centered mechanism in which PEX5 connects p38 MAPK–TFEB signaling, autophagic flux, and taurine biosynthesis to the senescence of lung fibroblasts. Its results suggest that the PEX5–taurine feedback loop may be relevant to age-associated lung dysfunction, while also emphasizing the need for orthogonal measurements of metabolism, viability, and senescence.

• Targeted SPP1 Inhibition in Tumor-Associated Myeloid Cells

  2026-08-25

  The reference study identifies a phenotypic strategy for reducing SPP1 expression in tumor-associated macrophages and packages complementary small-molecule hits in a TAM-avid polymeric nanoconstruct. Its lead, CANDI460, lowered SPP1 in vitro and in vivo and produced tumor remissions across murine models, supporting targeted myeloid reprogramming as a therapeutic direction.

• CHIR 99021 Trihydrochloride in Organoid Design

  2026-08-24

  CHIR 99021 trihydrochloride is more than a routine GSK-3 inhibitor: it can serve as a tunable variable for separating stemness, proliferation, and lineage diversification in organoid assays. This article connects its kinase pharmacology with a human intestinal organoid study to develop more informative experimental designs.

• YTHDF1 Phase Separation and SSC Fate Transition

  2026-08-24

  The reference study shows that YTHDF1 liquid-liquid phase separation helps convert spermatogonial stem cells into neural stem cell-like cells by activating the IκB–NF-κB–CCND1 pathway. Its perturbation and rescue experiments connect m6A-dependent RNA translation control with a broader protein–RNA condensate mechanism for cell-fate transition.

• Selective Magnetic Stimulation Targets GABRE in SCZ

  2026-08-23

  A 2025 Molecular Psychiatry study identifies the GABAA receptor epsilon subunit, GABRE, in the left prelimbic cortex as a causal and stimulation-responsive target in mouse models of schizophrenia-like behavior. By combining regionally precise magnetic stimulation with genetic loss- and gain-of-function experiments, the authors connect behavioral and synaptic rescue to p62/SQSTM1-mediated regulation of GABARAP-family sequestration.

8645 records 1/577 page Next 12345 下5页 Last page